ArticleClinical and vaccine immunology : CVI2006
Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.
Article in Clinical and vaccine immunology : CVI, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.Antimicrobial agents and chemotherapy · 2015Pooled it
- Transcriptomic dynamics reveals sequential acquisition of complement resistance during prolonged starvation of Trypanosoma cruzi epimastigoteMemorias do Instituto Oswaldo Cruz · 2026Article
- Quantitative monitoring of experimental and human leishmaniasis employing amastigote-specific genes.Parasitology · 2022Article
- An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.Acta parasitologica · 2022Article
- Article
- Comparative transcriptomics in Leishmania braziliensis: disclosing differential gene expression of coding and putative noncoding RNAs across developmental stages.RNA biology · 2019Article
- Genomic comparison of Trypanosoma conorhini and Trypanosoma rangeli to Trypanosoma cruzi strains of high and low virulence.BMC genomics · 2018Article
- Immunoproteomic Identification and Characterization of Leishmania Membrane Proteins as Non-Invasive Diagnostic Candidates for Clinical Visceral Leishmaniasis.Scientific reports · 2018Article
- Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species.Journal of clinical microbiology · 2017Article
- Amastin Knockdown in Leishmania braziliensis Affects Parasite-Macrophage Interaction and Results in Impaired Viability of Intracellular Amastigotes.PLoS pathogens · 2015Article
- The Comparative Genomics and Phylogenomics of Leishmania amazonensis Parasite.Evolutionary bioinformatics online · 2014Article
- The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models.DNA research : an international journal for rapid publication of reports on genes and genomes · 2013Article
- Distinct genomic organization, mRNA expression and cellular localization of members of two amastin sub-families present in Trypanosoma cruzi.BMC microbiology · 2013Article
- Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins.PloS one · 2013Article
- Diagnosis of visceral leishmaniasis: developments over the last decade.Parasitology research · 2012Review
- Trypanosoma cruzi: role of δ-amastin on extracellular amastigote cell invasion and differentiation.PloS one · 2012Article
- The evolution of amastin surface glycoproteins in trypanosomatid parasites.Molecular biology and evolution · 2010Article
- Deadenylation-independent stage-specific mRNA degradation in Leishmania.Nucleic acids research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amastin surface proteins belong to a large family of developmentally regulated proteins comprising up to 45 members that have recently been discovered in the genus Leishmania and are highly similar to the amastin proteins in Trypanosoma cruzi. All members of the amastin gene family contain a highly conserved 11-amino-acid (aa) signature at the N terminus, which is unique to the amastin proteins and to the Trypanosomatidae family. Recent studies have demonstrated that this region is highly protective in a mouse model. The goal of the present study was to evaluate the potential of the 50-aa N-terminal domain of amastin proteins harboring the conserved 11-aa amastin signature peptide as a relevant immune biomarker of cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). We report here the amastin-binding total immunoglobulins (IgG) and/or IgG subclasses in the sera of patients at different stages of CL (n=90) and VL (n=41). In CL cases, there is no significant difference in seroreactivities between active, recovered, and nonhealed cases. However, the amastin peptide-reactive antibodies were present at high titers in 19 of 20 sera collected from patients with active VL compared to sera from patients recovered from VL and asymptomatic cases of VL. These data suggest that the amastin signature peptide could represent a relevant biomarker for the serodiagnosis of VL and, most importantly, that it could permit differentiation among the different stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.